Literature DB >> 26265282

Effects of Advancing Gestation and Non-Caucasian Race on Ductus Arteriosus Gene Expression.

Nahid Waleh1, Anne Marie Barrette2, John M Dagle3, Allison Momany3, Chengshi Jin4, Nancy K Hills4, Elaine L Shelton5, Jeff Reese5, Ronald I Clyman6.   

Abstract

OBJECTIVE: To identify genes affected by advancing gestation and racial/ethnic origin in human ductus arteriosus (DA). STUDY
DESIGN: We collected 3 sets of DA tissue (n = 93, n = 89, n = 91; total = 273 fetuses) from second trimester pregnancies. We examined four genes, with DNA polymorphisms that distribute along racial lines, to identify "Caucasian" and "non-Caucasian" DA. We used real time polymerase chain reaction to measure RNA expression of 48 candidate genes involved in functional closure of the DA, and used multivariable regression analyses to examine the relationships between advancing gestation, "non-Caucasian" race, and gene expression.
RESULTS: Mature gestation and non-Caucasian race are significant predictors for identifying infants who will close their patent DA when treated with indomethacin. Advancing gestation consistently altered gene expression in pathways involved with oxygen-induced constriction (eg, calcium-channels, potassium-channels, and endothelin signaling), contractile protein maturation, tissue remodeling, and prostaglandin and nitric oxide signaling in all 3 tissue sets. None of the pathways involved with oxygen-induced constriction appeared to be altered in "non-Caucasian" DA. Two genes, SLCO2A1 and NOS3, (involved with prostaglandin reuptake/metabolism and nitric oxide production, respectively) were consistently decreased in "non-Caucasian" DA.
CONCLUSIONS: Prostaglandins and nitric oxide are the most important vasodilators opposing DA closure. Indomethacin inhibits prostaglandin production, but not nitric oxide production. Because decreased SLCO2A1 and NOS3 expression can lead to increased prostaglandin and decreased nitric oxide concentrations, we speculate that prostaglandin-mediated vasodilation may play a more dominant role in maintaining the "non-Caucasian" patent DA, making it more likely to close when inhibited by indomethacin.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26265282      PMCID: PMC4661123          DOI: 10.1016/j.jpeds.2015.07.011

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  77 in total

Review 1.  Genetics of patent ductus arteriosus susceptibility and treatment.

Authors:  Hanine Hajj; John M Dagle
Journal:  Semin Perinatol       Date:  2012-04       Impact factor: 3.300

2.  Mechanisms for ductus arteriosus closure.

Authors:  Flavio Coceani; Barbara Baragatti
Journal:  Semin Perinatol       Date:  2012-04       Impact factor: 3.300

Review 3.  Aortopathies: etiologies, genetics, differential diagnosis, prognosis and management.

Authors:  Timothy E Paterick; Julie A Humphries; Khawaja Afzal Ammar; M Fuad Jan; Rachel Loberg; Michelle Bush; Bijoy K Khandheria; A Jamil Tajik
Journal:  Am J Med       Date:  2013-06-22       Impact factor: 4.965

4.  PGE2 through the EP4 receptor controls smooth muscle gene expression patterns in the ductus arteriosus critical for remodeling at birth.

Authors:  Artiom Gruzdev; MyTrang Nguyen; Martina Kovarova; Beverly H Koller
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-02-11       Impact factor: 3.072

5.  Anatomic closure of the premature patent ductus arteriosus: The role of CD14+/CD163+ mononuclear cells and VEGF in neointimal mound formation.

Authors:  Nahid Waleh; Steven Seidner; Donald McCurnin; Luis Giavedoni; Vida Hodara; Susan Goelz; Bao Mei Liu; Christine Roman; Ronald I Clyman
Journal:  Pediatr Res       Date:  2011-10       Impact factor: 3.756

6.  Oxygen-sensitive Kv channel gene transfer confers oxygen responsiveness to preterm rabbit and remodeled human ductus arteriosus: implications for infants with patent ductus arteriosus.

Authors:  Bernard Thébaud; Evangelos D Michelakis; Xi-Chen Wu; Rohit Moudgil; Michael Kuzyk; Jason R B Dyck; Gwyneth Harry; Kyoko Hashimoto; Alois Haromy; Ivan Rebeyka; Stephen L Archer
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

7.  Prostaglandin E2--mediated relaxation of the ductus arteriosus: effects of gestational age on g protein-coupled receptor expression, signaling, and vasomotor control.

Authors:  Nahid Waleh; Hiroki Kajino; Anne Marilise Marrache; David Ginzinger; Christine Roman; Steven R Seidner; Timothy J M Moss; Jean-Claude Fouron; Alejandro Vazquez-Tello; Sylvain Chemtob; Ronald I Clyman
Journal:  Circulation       Date:  2004-10-11       Impact factor: 29.690

8.  Factors determining the loss of ductus arteriosus responsiveness to prostaglandin E.

Authors:  R I Clyman; F Mauray; C Roman; M A Heymann; B Payne
Journal:  Circulation       Date:  1983-08       Impact factor: 29.690

9.  Genetic architecture of skin and eye color in an African-European admixed population.

Authors:  Sandra Beleza; Nicholas A Johnson; Sophie I Candille; Devin M Absher; Marc A Coram; Jailson Lopes; Joana Campos; Isabel Inês Araújo; Tovi M Anderson; Bjarni J Vilhjálmsson; Magnus Nordborg; António Correia E Silva; Mark D Shriver; Jorge Rocha; Gregory S Barsh; Hua Tang
Journal:  PLoS Genet       Date:  2013-03-21       Impact factor: 5.917

10.  Transcription profiles of endothelial cells in the rat ductus arteriosus during a perinatal period.

Authors:  Norika Mengchia Liu; Tomohiro Yokota; Shun Maekawa; Ping Lü; Yun-Wen Zheng; Inbun Tei; Hideki Taniguchi; Utako Yokoyama; Takashi Kato; Susumu Minamisawa
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

View more
  7 in total

Review 1.  Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins.

Authors:  Elaine L Shelton; Gautam K Singh; Colin G Nichols
Journal:  Semin Perinatol       Date:  2018-05-10       Impact factor: 3.300

Review 2.  Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.

Authors:  Tamorah R Lewis; Elaine L Shelton; Sara L Van Driest; Prince J Kannankeril; Jeff Reese
Journal:  Semin Fetal Neonatal Med       Date:  2018-02-24       Impact factor: 3.926

Review 3.  Prediction of Therapeutic Response to Cyclooxygenase Inhibitors in Preterm Infants with Patent Ductus Arteriosus.

Authors:  Yang Hu; Hongfang Jin; Yi Jiang; Junbao Du
Journal:  Pediatr Cardiol       Date:  2018-02-21       Impact factor: 1.655

Review 4.  Transcriptional profiling of the ductus arteriosus: Comparison of rodent microarrays and human RNA sequencing.

Authors:  Michael T Yarboro; Matthew D Durbin; Jennifer L Herington; Elaine L Shelton; Tao Zhang; Cris G Ebby; Jason Z Stoller; Ronald I Clyman; Jeff Reese
Journal:  Semin Perinatol       Date:  2018-05-10       Impact factor: 3.300

5.  Identification of differentially regulated genes in human patent ductus arteriosus.

Authors:  Pratik Parikh; Haiqing Bai; Michael F Swartz; George M Alfieris; David A Dean
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-28

Review 6.  Patent Ductus Arteriosus of the Preterm Infant.

Authors:  Shannon E G Hamrick; Hannes Sallmon; Allison T Rose; Diego Porras; Elaine L Shelton; Jeff Reese; Georg Hansmann
Journal:  Pediatrics       Date:  2020-11       Impact factor: 7.124

7.  Effects of antenatal betamethasone on preterm human and mouse ductus arteriosus: comparison with baboon data.

Authors:  Elaine L Shelton; Nahid Waleh; Erin J Plosa; John T Benjamin; Ginger L Milne; Christopher W Hooper; Noah J Ehinger; Stanley Poole; Naoko Brown; Steven Seidner; Donald McCurnin; Jeff Reese; Ronald I Clyman
Journal:  Pediatr Res       Date:  2018-07-06       Impact factor: 3.756

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.